The Johns Hopkins University

Champions Biotechnology, Inc.

Antonio Jimeno

Manuel Medina Hidalgo

Saeed R Khan

Gurulinsappa Hallur

The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction of stabilization of at least one sign or symptom of cancer.

ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors

The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction or stabilization of at least one sign or symptom of cancer.

A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6and 7were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell lines. 6was more effective than compound 1 in causing apoptosis of MCF-7 cells. When compared to other drugs with a similar mechanism of action, 6retained significant ability to inhibit tubulin assembly, with an ICof 2.1 &#x3bc;M.

Growing community of inventors

Englewood, CO, United States of America

Antonio Jimeno